First-line empiric antibiotic therapy for community-acquired pneumonia

References

1. [1]

   Kamat IS, Ramachandran V, Eswaran H et al.. “Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31241140 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
2. [2]

   Jasper AS, Musuuza JS, Tischendorf JS et al.. “Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32296816 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
3. [3]

   Kuitunen I, Jääskeläinen J, Korppi M et al.. “Antibiotic Treatment Duration for Community-Acquired Pneumonia in Outpatient Children in High-Income Countries-A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35579504 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
4. [4]

   Briel M, Spoorenberg SMC, Snijders D et al.. “Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29020323 ↗

   L2SR_OBSCited in: Bottom Line, Current Evidence and Standard
5. [5]

   Folgori L, Bielicki J, Ruiz B et al.. “Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.” The Lancet. Infectious diseases (2016). PMID: 27375212 ↗

   L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
6. [6]

   Metlay JP, Waterer GW, Long AC et al.. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.” American journal of respiratory and critical care medicine (2019). PMID: 31573350 ↗

   L2GUIDELINECited in: Bottom Line
7. [7]

   Jones BE, Ramirez JA, Oren E et al.. “Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2026). PMID: 40679934 ↗

   L2GUIDELINECited in: Bottom Line
8. [8]

   Schweitzer VA, van Heijl I, Boersma WG et al.. “Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial.” The Lancet. Infectious diseases (2021). PMID: 34627499 ↗

   L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
9. [9]

   Barrera CM, Mykietiuk A, Metev H et al.. “Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).” The Lancet. Infectious diseases (2016). PMID: 26852726 ↗

   L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
10. [10]

    Taboada M, Melnick D, Iaconis JP et al.. “Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.” The Journal of antimicrobial chemotherapy (2015). PMID: 26702925 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
11. [11]

    Odeyemi YE, Tekin A, Schanz CC et al.. “Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40378193 ↗

    L3COHORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
12. [12]

    Dequin PF, Meziani F, Quenot JP et al.. “Hydrocortisone in Severe Community-Acquired Pneumonia.” The New England journal of medicine (2023). PMID: 36942789 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
13. [13]

    Lucinde RK, Gathuri H, Mwaniki P et al.. “A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.” The New England journal of medicine (2025). PMID: 41159889 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
14. [14]

    Stets R, Popescu M, Gonong JR et al.. “Omadacycline for Community-Acquired Bacterial Pneumonia.” The New England journal of medicine (2019). PMID: 30726692 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
15. [15]

    Dinh A, Ropers J, Duran C et al.. “Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.” Lancet (London, England) (2021). PMID: 33773631 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
16. [16]

    Tansarli GS, Mylonakis E. “Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.” Antimicrobial agents and chemotherapy (2018). PMID: 29987137 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
17. [17]

    Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I et al.. “Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.” JAMA (2026). PMID: 41359996 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
18. [18]

    Bielicki JA, Stöhr W, Barratt S et al.. “Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.” JAMA (2021). PMID: 34726708 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
19. [19]

    Tannous A, Levinson SL, Bolognese J et al.. “Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2020). PMID: 32690640 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
20. [20]

    Groeneveld GH, van der Reyden TJ, Joosten SA et al.. “Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.” The Journal of antimicrobial chemotherapy (2019). PMID: 31106377 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
21. [21]

    Chen YC, Hsu WY, Chang TH. “Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.” Emerging infectious diseases (2020). PMID: 32568052 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
22. [22]

    Wu H, Cheng Z, Ding F et al.. “Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia.” Antimicrobial agents and chemotherapy (2026). PMID: 41778914 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
23. [23]

    Deshpande A, Klompas M, Guo N et al.. “Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37011018 ↗

    L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
24. [24]

    Klompas M, Al-Hasan M, Al Mohajer M et al.. “Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41340493 ↗

    L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
25. [25]

    Biebelberg B, Chen T, McKenna C et al.. “Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41378862 ↗

    L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
26. [26]

    Ambroggio L, Cotter J, Hall M et al.. “Management of Pediatric Pneumonia: A Decade After the Pediatric Infectious Diseases Society and Infectious Diseases Society of America Guideline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37352841 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon
27. [27]

    Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
28. [28]

    Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗

    L3COHORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
29. [29]

    Long B, Gottlieb M. “2025 guideline updates for community-acquired pneumonia diagnosis and management.” The American journal of emergency medicine (2026). PMID: 42127879 ↗

    L2GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
30. [30]

    Potter-Schwartz L, Swe MM, Sharland M et al.. “Effectiveness of amoxicillin and amoxicillin-clavulanate for the treatment of community-acquired pneumonia in adults and children: a systematic review and meta-analysis.” BMJ open (2026). PMID: 42097647 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
31. [31]

    Nasr R, Rahman AA, ElHadi N et al.. “Macrolides usage as anti-inflammatory agents in the treatment of community-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42087250 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
32. [32]

    Laterre PF, Colin G, Dequin PF et al.. “CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.” The Lancet. Infectious diseases (2019). PMID: 31056427 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
33. [33]

    Hashmi M, Haniffa R, Jayakumar D et al.. “Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).” Critical care medicine (2026). PMID: 42101205 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
34. [34]

    Pereira PC, de Lima CJ, Fernandes AB et al.. “Effects of photobiomodulation by infrared LED-therapy on improving cardiopulmonary functions and hematologic parameters in patients with community-acquired pneumonia (CAP).” Respiratory medicine (2026). PMID: 42009264 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
35. [35]

    Stylianakis E, Kakavoulis N, Foutadakis S et al.. “Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial.” EBioMedicine (2026). PMID: 41934919 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
36. [36]

    Michels EHA, Dequin PF, Butler JM et al.. “Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.” The Lancet. Respiratory medicine (2026). PMID: 41856148 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
37. [37]

    Pinot J, Delory T, Pétrier M et al.. “Clinical data, chest X-ray or C-reactive protein to initiate antibiotic therapy in outpatients with suspected community-acquired pneumonia: a prospective, randomized, controlled, digital case vignette study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 41839418 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
38. [38]

    Wu M, Han S, Li H. “Lefamulin versus omadacycline for community acquired bacterial pneumonia: a systematic review and anchored indirect treatment comparison using moxifloxacin as the common comparator.” Journal of comparative effectiveness research (2026). PMID: 41823576 ↗

    L2SR_OBSCited in: Bottom Line, Current Evidence and Standard
39. [39]

    Takeda K, Takazono T, Ashizawa N et al.. “Lascufloxacin switch therapy versus ampicillin/sulbactam for older patients with community-acquired pneumonia in Japan (STEP study): a study protocol for a multicentre open-label randomised controlled non-inferiority trial.” BMJ open (2026). PMID: 42379706 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
40. [40]

    Reyes LF, Conway Morris A, Serrano-Mayorga C et al.. “Community-acquired pneumonia.” Lancet (London, England) (2025). PMID: 41110447 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
41. [41]

    Aliberti S, Dela Cruz CS, Amati F et al.. “Community-acquired pneumonia.” Lancet (London, England) (2021). PMID: 34481570 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
42. [42]

    Huang L, Price EP, Sarovich DS et al.. “Bacteremia and Community-Acquired Pneumonia Caused by Pantoea stewartii Subspecies indologenes, Australia.” Emerging infectious diseases (2025). PMID: 39983690 ↗

    L4CASE_REPORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
43. [43]

    Moon J, Jang Y, Kim N et al.. “Diagnosis of Haemophilus influenzae Pneumonia by Nanopore 16S Amplicon Sequencing of Sputum.” Emerging infectious diseases (2018). PMID: 29989532 ↗

    L4CASE_REPORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
44. [44]

    Vaughn VM, Dickson RP, Horowitz JK et al.. “Community-Acquired Pneumonia: A Review.” JAMA (2024). PMID: 39283629 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
45. [45]

    Pirracchio R, Venkatesh B, Legrand M. “Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review.” JAMA (2024). PMID: 38865154 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
46. [46]

    Rhodes NJ, Rohani R, Yarnold PR et al.. “Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2022). PMID: 36472425 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon
47. [47]

    Wicha WW, Henson C, Webbley K et al.. “Tissue Distribution of [14C]-Lefamulin into the Urogenital Tract in Rats.” Antimicrobial agents and chemotherapy (2022). PMID: 35862748 ↗

    L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
48. [48]

    File TM, Ramirez JA, Wilde AM. “New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).” Antimicrobial agents and chemotherapy (2025). PMID: 39817764 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
49. [49]

    Oliver MB, Fong K, Certain L et al.. “Validation of a Community-Acquired Pneumonia Score To Improve Empiric Antibiotic Selection at an Academic Medical Center.” Antimicrobial agents and chemotherapy (2021). PMID: 33257449 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
50. [50]

    Zheng Y, Liu SP, Xu BP et al.. “Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2018). PMID: 29941652 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
51. [51]

    Paukner S, Gelone SP, Arends SJR et al.. “Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).” Antimicrobial agents and chemotherapy (2019). PMID: 30670415 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
52. [52]

    Falcone M, Russo A, Shindo Y et al.. “A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2019). PMID: 30509940 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
53. [53]

    Malinis M, Abbo L, Vazquez JA et al.. “Community-acquired pneumonia: a US perspective on the guideline gap.” The Journal of antimicrobial chemotherapy (2024). PMID: 38693426 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon
54. [54]

    Roger C, Allaouchiche B, Quintão De Moraes D et al.. “Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40754699 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
55. [55]

    Viasus D, Simonetti AF, Garcia-Vidal C et al.. “Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.” The Journal of antimicrobial chemotherapy (2016). PMID: 27798219 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
56. [56]

    Greco Kinney A, Kovacic Scherrer N, Sarkar S et al.. “β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.” The Journal of antimicrobial chemotherapy (2023). PMID: 37814829 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon
57. [57]

    Boutzoukas AE, Mackow N, Giri A et al.. “Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections.” The Journal of antimicrobial chemotherapy (2024). PMID: 39236214 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard, On the Horizon
58. [58]

    Rodvold KA. “Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.” The Journal of antimicrobial chemotherapy (2019). PMID: 30949709 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
59. [59]

    Cantón R, Akova M, Langfeld K et al.. “Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065724 ↗

    L5OTHERCited in: Bottom Line, Current Evidence and Standard
60. [60]

    Sazawal S, Black RE. “Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials.” The Lancet. Infectious diseases (2003). PMID: 12954560 ↗

    L2SR_OBSCited in: Background: Evolution of Treatment
61. [61]

    Zhong NS, Sun T, Zhuo C et al.. “Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.” The Lancet. Infectious diseases (2014). PMID: 25539586 ↗

    L1RCTCited in: Background: Evolution of Treatment
62. [62]

    Contopoulos-Ioannidis DG, Ioannidis JP, Chew P et al.. “Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections.” The Journal of antimicrobial chemotherapy (2001). PMID: 11679558 ↗

    L1SR_MA_RCTCited in: Background: Evolution of Treatment
63. [63]

    Bonten MJ, Huijts SM, Bolkenbaas M et al.. “Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.” The New England journal of medicine (2015). PMID: 25785969 ↗

    L1RCTCited in: Background: Evolution of Treatment
64. [64]

    Blum CA, Nigro N, Briel M et al.. “Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2015). PMID: 25608756 ↗

    L1RCTCited in: Background: Evolution of Treatment
65. [65]

    Siempos II, Vardakas KZ, Kopterides P et al.. “Adjunctive therapies for community-acquired pneumonia: a systematic review.” The Journal of antimicrobial chemotherapy (2008). PMID: 18641037 ↗

    L2SR_OBSCited in: Background: Evolution of Treatment
66. [66]

    Oosterheert JJ, Bonten MJ, Hak E et al.. “How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.” The Journal of antimicrobial chemotherapy (2003). PMID: 12972448 ↗

    L2SR_OBSCited in: Background: Evolution of Treatment
67. [67]

    Torres A, Sibila O, Ferrer M et al.. “Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.” JAMA (2015). PMID: 25688779 ↗

    L1RCTCited in: Background: Evolution of Treatment
68. [68]

    Rubino CM, Bhavnani SM, Forrest A et al.. “Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.” Antimicrobial agents and chemotherapy (2011). PMID: 21968360 ↗

    L1RCTCited in: Background: Evolution of Treatment
69. [69]

    Drehobl M, Bianchi P, Keyserling CH et al.. “Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.” Antimicrobial agents and chemotherapy (1997). PMID: 9210689 ↗

    L1RCTCited in: Background: Evolution of Treatment
70. [70]

    Dean NC, Sperry P, Wikler M et al.. “Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.” Antimicrobial agents and chemotherapy (2006). PMID: 16569825 ↗

    L1RCTCited in: Background: Evolution of Treatment
71. [71]

    Marrie TJ. “Community-acquired pneumonia in the elderly.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2000). PMID: 11049791 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
72. [72]

    Hidron AI, Low CE, Honig EG et al.. “Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia.” The Lancet. Infectious diseases (2009). PMID: 19467478 ↗

    L4CASE_REPORTCited in: Background: Evolution of Treatment
73. [73]

    Barlow GD, Lamping DL, Davey PG et al.. “Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers.” The Lancet. Infectious diseases (2003). PMID: 12901890 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
74. [74]

    Principi N, Esposito S. “Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections.” The Lancet. Infectious diseases (2001). PMID: 11871806 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
75. [75]

    Chertow DS, Memoli MJ. “Bacterial coinfection in influenza: a grand rounds review.” JAMA (2013). PMID: 23321766 ↗

    L4CASE_REPORTCited in: Background: Evolution of Treatment
76. [76]

    Gordin FM, Masur H. “Current approaches to tuberculosis in the United States.” JAMA (2012). PMID: 22797646 ↗

    L4CASE_REPORTCited in: Background: Evolution of Treatment
77. [77]

    Prina E, Ranzani OT, Torres A. “Community-acquired pneumonia.” Lancet (London, England) (2015). PMID: 26277247 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
78. [78]

    Ruuskanen O, Lahti E, Jennings LC et al.. “Viral pneumonia.” Lancet (London, England) (2011). PMID: 21435708 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
79. [79]

    File TM. “Community-acquired pneumonia.” Lancet (London, England) (2003). PMID: 14683661 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
80. [80]

    Brown PD, Lerner SA. “Community-acquired pneumonia.” Lancet (London, England) (1998). PMID: 9788476 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
81. [81]

    Bastida T, Pérez-Vázquez M, Campos J et al.. “Levofloxacin treatment failure in Haemophilus influenzae pneumonia.” Emerging infectious diseases (2003). PMID: 14718097 ↗

    L4CASE_REPORTCited in: Background: Evolution of Treatment
82. [82]

    Gleason PP, Kapoor WN, Stone RA et al.. “Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.” JAMA (1997). PMID: 9207335 ↗

    L5OTHERCited in: Background: Evolution of Treatment
83. [83]

    Micek ST, Kollef KE, Reichley RM et al.. “Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.” Antimicrobial agents and chemotherapy (2007). PMID: 17682100 ↗

    L5OTHERCited in: Background: Evolution of Treatment
84. [84]

    Dryden M, Hand K, Davey P. “Antibiotics for community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2009). PMID: 19820250 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
85. [85]

    Kovaleva A, Remmelts HH, Rijkers GT et al.. “Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review.” The Journal of antimicrobial chemotherapy (2011). PMID: 22190609 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
86. [86]

    Klugman KP, Lonks JR. “Hidden epidemic of macrolide-resistant pneumococci.” Emerging infectious diseases (2005). PMID: 15963272 ↗

    L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment
87. [87]

    Blair JE, Chang YH, Cheng MR et al.. “Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.” Emerging infectious diseases (2014). PMID: 24865953 ↗

    L5OTHERCited in: Background: Evolution of Treatment
88. [88]

    Valdivia L, Nix D, Wright M et al.. “Coccidioidomycosis as a common cause of community-acquired pneumonia.” Emerging infectious diseases (2006). PMID: 16707052 ↗

    L5OTHERCited in: Background: Evolution of Treatment
89. [89]

    MacDougall C, Guglielmo BJ, Maselli J et al.. “Antimicrobial drug prescribing for pneumonia in ambulatory care.” Emerging infectious diseases (2005). PMID: 15757551 ↗

    L5OTHERCited in: Background: Evolution of Treatment
90. [90]

    Watkins RR, File TM. “Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32221520 ↗

    L5REVIEW_NARRATIVECited in: Current Evidence and Standard
91. [91]

    Hojat LS, Laguio-Vila MR, Sullivan LR et al.. “We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41340515 ↗

    L5OTHERCited in: Current Evidence and Standard
92. [92]

    Stotts C, Corrales-Medina VF, deKemp RA et al.. “Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.” BMJ open (2026). PMID: 41781043 ↗

    L2TRIAL_NONRANDOMCited in: Current Evidence and Standard
93. [93]

    Lepak AJ, Zhao M, Marchillo K et al.. “In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.” Antimicrobial agents and chemotherapy (2020). PMID: 31712210 ↗

    L5OTHERCited in: Current Evidence and Standard
94. [94]

    MacLauchlin C, Schneider SE, Keedy K et al.. “Metabolism, Excretion, and Mass Balance of Solithromycin in Humans.” Antimicrobial agents and chemotherapy (2018). PMID: 29507061 ↗

    L5OTHERCited in: Current Evidence and Standard
95. [95]

    Torumkuney D, Kundu S, Vu GV et al.. “Country data on AMR in Vietnam in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065731 ↗

    L5OTHERCited in: Current Evidence and Standard
96. [96]

    Torumkuney D, de la Torre C, Langfeld K et al.. “Country data on AMR in Mexico in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065728 ↗

    L5OTHERCited in: Current Evidence and Standard
97. [97]

    Klein EY, Mojica N, Jiang W et al.. “Trends in Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 29020322 ↗

    L5OTHERCited in: Applicability and Caveats
98. [98]

    Butler AM, Nickel KB, Olsen MA et al.. “Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 39442057 ↗

    L5OTHERCited in: Applicability and Caveats
99. [99]

    Smith DJ, Free RJ, Thompson GR et al.. “Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients With Community-Acquired Pneumonia for Primary and Urgent Care Providers.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37802909 ↗

    L5OTHERCited in: Applicability and Caveats, On the Horizon
100. [100]

     Christensen MA, Nevers M, Ying J et al.. “Simulated Adoption of 2019 Community-Acquired Pneumonia Guidelines Across 114 Veterans Affairs Medical Centers: Estimated Impact on Culturing and Antibiotic Selection in Hospitalized Patients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33512530 ↗

     L5OTHERCited in: Applicability and Caveats
101. [101]

     Yi SH, Hatfield KM, Baggs J et al.. “Duration of Antibiotic Use Among Adults With Uncomplicated Community-Acquired Pneumonia Requiring Hospitalization in the United States.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29126268 ↗

     L5OTHERCited in: Applicability and Caveats
102. [102]

     Vaughn VM, Ratz D, Greene MT et al.. “Antibiotic Stewardship Strategies and Their Association With Antibiotic Overuse After Hospital Discharge: An Analysis of the Reducing Overuse of Antibiotics at Discharge (Road) Home Framework.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35143638 ↗

     L5OTHERCited in: Applicability and Caveats
103. [103]

     Kurotschka PK, Bentivegna M, Hulme C et al.. “Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis.” Journal of general internal medicine (2024). PMID: 38360961 ↗

     L2SR_OBSCited in: Applicability and Caveats
104. [104]

     Furukawa Y, Luo Y, Funada S et al.. “Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis.” BMJ open (2023). PMID: 36948555 ↗

     L2SR_OBSCited in: Applicability and Caveats
105. [105]

     R Marques I, P Calvi I, A Cruz S et al.. “Shorter versus longer duration of Amoxicillin-based treatment for pediatric patients with community-acquired pneumonia: a systematic review and meta-analysis.” European journal of pediatrics (2022). PMID: 36066660 ↗

     L2SR_OBSCited in: Applicability and Caveats
106. [106]

     Williams DJ, Creech CB, Walter EB et al.. “Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.” JAMA pediatrics (2022). PMID: 35040920 ↗

     L1RCTCited in: Applicability and Caveats
107. [107]

     Israelsen SB, Tingsgård S, Thorlacius-Ussing L et al.. “Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial.” BMJ open (2023). PMID: 37479519 ↗

     L2TRIAL_NONRANDOMCited in: Applicability and Caveats
108. [108]

     Ding HF, Li F, Xu YX et al.. “Changes in inflammatory markers and efficacy analysis of continuous subcutaneous insulin infusion in senior patients with type 2 diabetes mellitus hospitalized with community-acquired pneumonia: a randomized controlled trial.” European geriatric medicine (2024). PMID: 38194052 ↗

     L1RCTCited in: Applicability and Caveats
109. [109]

     Torumkuney D, Kozlov R, Sidorenko S et al.. “Country data on AMR in Russia in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.” The Journal of antimicrobial chemotherapy (2022). PMID: 36065732 ↗

     L5OTHERCited in: Applicability and Caveats
110. [110]

     Bergmann F, Pracher L, Sawodny R et al.. “Efficacy and Safety of Corticosteroid Therapy for Community-Acquired Pneumonia: A Meta-Analysis and Meta-Regression of Randomized, Controlled Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37876267 ↗

     L2SR_OBSCited in: On the Horizon
111. [111]

     Gasoyan H, Deshpande A, Imrey PB et al.. “Potential Implications of Using Locally Validated Risk Factors for Drug-Resistant Pathogens in Patients With Community-Acquired Pneumonia in US Hospitals: A Cross-Sectional Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39226148 ↗

     L5OTHERCited in: On the Horizon
112. [112]

     Ho EC, Olson KE, Butler M et al.. “Clinical Impact of Pleural Fluid Streptococcus pneumoniae Polymerase Chain Reaction Testing in Children With Complicated Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39207213 ↗

     L5OTHERCited in: On the Horizon
113. [113]

     Eynath Y, McNeil R, Buchrits S et al.. “Chloramphenicol versus ceftriaxone for the treatment of pneumonia and sepsis in elderly patients with advanced dementia and functional disability. A propensity-weighted retrospective cohort study.” The Journal of antimicrobial chemotherapy (2024). PMID: 39308334 ↗

     L3COHORTCited in: On the Horizon
114. [114]

     Prizão VM, Martins OC, de Hollanda Morais BAA et al.. “Effectiveness of macrolides as add-on therapy to beta-lactams in community-acquired pneumonia: A meta-analysis of randomized controlled trials.” European journal of clinical pharmacology (2024). PMID: 39551892 ↗

     L1SR_MA_RCTCited in: On the Horizon
115. [115]

     Donà D, Brigadoi G, Grandinetti R et al.. “Treatment of mild to moderate community-acquired pneumonia in previously healthy children: an Italian intersociety consensus (SIPPS-SIP-SITIP-FIMP-SIAIP-SIMRI-FIMMG-SIMG).” Italian journal of pediatrics (2024). PMID: 39427174 ↗

     L2SR_OBSCited in: On the Horizon
116. [116]

     Akinosoglou K, Leventogiannis K, Tasouli E et al.. “Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial.” International journal of antimicrobial agents (2024). PMID: 39647798 ↗

     L1RCTCited in: On the Horizon
117. [117]

     Cantais A, Pillet S, Rigaill J et al.. “Impact of respiratory pathogens detection by a rapid multiplex polymerase chain reaction assay on the management of community-acquired pneumonia for children at the paediatric emergency department. A randomized controlled trial, the Optimization of Pneumonia Acute Care (OPTIPAC) study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 39111697 ↗

     L1RCTCited in: On the Horizon
118. [118]

     Li Y, Zhu D, Sun S et al.. “A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.” International journal of antimicrobial agents (2024). PMID: 38851462 ↗

     L1RCTCited in: On the Horizon
119. [119]

     Kok HC, McCallum GB, Yerkovich ST et al.. “Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial.” The Pediatric infectious disease journal (2024). PMID: 38830139 ↗

     L1RCTCited in: On the Horizon
120. [120]

     Dinh A, Duran C, Ropers J et al.. “Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 38734138 ↗

     L1RCTCited in: On the Horizon
121. [121]

     Markussen DL, Wathne JS, Ritz C et al.. “Determinants of non-adherence to antibiotic treatment guidelines in hospitalized adults with suspected community-acquired pneumonia: a prospective study.” Antimicrobial resistance and infection control (2024). PMID: 39580437 ↗

     L2TRIAL_NONRANDOMCited in: On the Horizon
122. [122]

     Paukner S, Mendes RE, Arends SJR et al.. “7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.” The Journal of antimicrobial chemotherapy (2024). PMID: 38113528 ↗

     L5OTHERCited in: On the Horizon
123. [123]

     van Os W, Zeitlinger M. “Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.” The Journal of antimicrobial chemotherapy (2024). PMID: 38174805 ↗

     L5OTHERCited in: On the Horizon